Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/1753-0407.13084 http://scihub22266oqcxt.onion/10.1111/1753-0407.13084 32638507!7361557!32638507     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32638507&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Diabetes 2020 ; 12 (12): 909-918 Nephropedia Template TP {{tp|p=32638507|t=2020. The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19 |pdf=|usr=}}{{32638507}} gab.com Text The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19 JO: J Diabetes http://www.kidney.de/pget.php?&tw=1&pmid=32638507 #FOAvip BACKGROUND: Although type 2 diabetes mellitus (T2DM) patients with coronavirus disease 2019 (COVID-19) develop a more severe condition compared to those without diabetes, the mechanisms for this are unknown. Moreover, the impact of treatment with antihyperglycemic drugs and glucocorticoids is unclear. METHODS: From 1584 COVID-19 patients, 364 severe/critical COVID-19 patients with clinical outcome were enrolled for the final analysis, and patients without preexisting T2DM but elevated glucose levels were excluded. Epidemiological data were obtained and clinical status evaluation carried out to assess the impact of T2DM and its management on clinical outcomes. RESULTS: Of 364 enrolled severe COVID-19 inpatients, 114 (31.3%) had a history of T2DM. Twenty-seven (23.7%) T2DM patients died, who had more severe inflammation, coagulation activation, myocardia injury, hepatic injury, and kidney injury compared with non-DM patients. In severe COVID-19 patients with T2DM, we demonstrated a higher risk of all-cause fatality with glucocorticoid treatment (adjusted hazard ratio [HR], 3.61; 95% CI, 1.14-11.46; P = .029) and severe hyperglycemia (fasting plasma glucose >/=11.1 mmol/L; adjusted HR, 11.86; 95% CI, 1.21-116.44; P = .034). CONCLUSIONS: T2DM status aggravated the clinical condition of COVID-19 patients and increased their critical illness risk. Poor fasting blood glucose (>/= 11.1 mmol/L) and glucocorticoid treatment are associated with poor prognosis for T2DM patients with severe COVID-19. Twit Text FOAVip The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19 ????J Diabetes http://www.kidney.de/pget.php?&tw=1&pmid=32638507 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32638507 #FOAvip English Wikipedia <ref>{{Cite pmid|32638507}}</ref> The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19 #MMPMID32638507 Xu Z; Wang Z; Wang S; Ye Y; Luo D; Wan L; Yu A; Sun L; Tesfaye S; Meng Q; Gao L J Diabetes 2020[Dec]; 12 (12): 909-918 PMID32638507show ga BACKGROUND: Although type 2 diabetes mellitus (T2DM) patients with coronavirus disease 2019 (COVID-19) develop a more severe condition compared to those without diabetes, the mechanisms for this are unknown. Moreover, the impact of treatment with antihyperglycemic drugs and glucocorticoids is unclear. METHODS: From 1584 COVID-19 patients, 364 severe/critical COVID-19 patients with clinical outcome were enrolled for the final analysis, and patients without preexisting T2DM but elevated glucose levels were excluded. Epidemiological data were obtained and clinical status evaluation carried out to assess the impact of T2DM and its management on clinical outcomes. RESULTS: Of 364 enrolled severe COVID-19 inpatients, 114 (31.3%) had a history of T2DM. Twenty-seven (23.7%) T2DM patients died, who had more severe inflammation, coagulation activation, myocardia injury, hepatic injury, and kidney injury compared with non-DM patients. In severe COVID-19 patients with T2DM, we demonstrated a higher risk of all-cause fatality with glucocorticoid treatment (adjusted hazard ratio [HR], 3.61; 95% CI, 1.14-11.46; P = .029) and severe hyperglycemia (fasting plasma glucose >/=11.1 mmol/L; adjusted HR, 11.86; 95% CI, 1.21-116.44; P = .034). CONCLUSIONS: T2DM status aggravated the clinical condition of COVID-19 patients and increased their critical illness risk. Poor fasting blood glucose (>/= 11.1 mmol/L) and glucocorticoid treatment are associated with poor prognosis for T2DM patients with severe COVID-19. |Aged[MESH] |Biomarkers/*analysis[MESH] |Blood Glucose/analysis[MESH] |COVID-19/complications/*epidemiology/transmission/virology[MESH] |China/epidemiology[MESH] |Diabetes Mellitus, Type 2/*drug therapy/physiopathology/virology[MESH] |Female[MESH] |Follow-Up Studies[MESH] |Glucocorticoids/*therapeutic use[MESH] |Humans[MESH] |Hypoglycemic Agents/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Prognosis[MESH] |SARS-CoV-2/*isolation & purification[MESH]The impact of type 2 diabetes and its management on the prognosis of p(epmc).pdf DeepDyve Pubget Overpricing